Search
Framycetin
go.drugbank.com/drugs/DB00452ApprovedInvestigationalA component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)
CP-122721
go.drugbank.com/drugs/DB05421ExperimentalCP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
Covax-19™
go.drugbank.com/drugs/DB15846InvestigationalIt uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).
Potassium triiodide
go.drugbank.com/drugs/DB14492InvestigationalCategories: Compounds used in a research, industrial, or household settingOltipraz
go.drugbank.com/drugs/DB12539InvestigationalOltipraz has been used in trials studying the treatment and prevention of Lung Cancer, Liver Fibrosis, Liver Cirrhosis, and Non-alcoholic Fatty Liver Disease.
Categories: Compounds used in a research, industrial, or household settingTempol
go.drugbank.com/drugs/DB12449InvestigationalTempol has been used in trials studying the treatment of Anal Cancer.
Categories: Compounds used in a research, industrial, or household settingButhionine sulfoximine
go.drugbank.com/drugs/DB12870InvestigationalButhionine sulfoximine has been used in trials studying the treatment of Neuroblastoma and Melanoma (Skin).
Categories: Compounds used in a research, industrial, or household settingPlitidepsin
go.drugbank.com/drugs/DB04977InvestigationalAplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is _Aplidium albicans_. … Aplidine is also of interest as a potential treatment for some leukemias.
Pucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigational[A257296] It is being investigated in other cancers. … Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.
Velaglucerase alfa
go.drugbank.com/drugs/DB06720ApprovedAdditionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease. … Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase.